Locations
Cambridge, UK · Streetly End, Cambridge CB21 4RP, UK
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series A
founded in
2022
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, focused on harnessing T cell biology to create safe and effective treatments for cancer and autoimmune diseases. Utilizing their proprietary Op Ti Mus® platform, they develop optimal TCR-based therapeutics that target multiple classes of cancer, aiming to reshape the clinical landscape with first-in-class drugs. The company combines expertise in mouse genome engineering, biopharmaceutical drug development, single cell genomics, machine-learning, and structural biology, fostering a culture of creativity and collaboration to drive innovation in T cell receptor-based medicines.
Something looks off?On-site & Remote